Allergy Shot for Dog Allergies: Yes, It Exists — With Important Caveats
Yes, there is an allergy shot for HUMANS allergic to dogs — it's subcutaneous immunotherapy (SCIT) using dog-allergen extract. It is NOT a veterinary product. Cytopoint (Zoetis lokivetmab) and Apoquel (Zoetis oclacitinib) are dog-specific veterinary treatments. Dog SCIT evidence is 'poor and conflicting' per Smith 2016. Before starting, test for Can f 5: 16.5% of dog-sensitized adults can adopt a female dog instead.
8 peer-reviewed sources
Yes, there is an allergy shot for humans allergic to dogs — SCIT using dog allergen extract administered by an allergist. Dog extracts are not FDA-standardized; efficacy is 'poor and conflicting' per Smith 2016. Can f 5 testing may reveal a no-shot alternative for 16.5% of patients.
The essentials
Yes, there is an allergy shot for HUMANS allergic to dogs — it's subcutaneous immunotherapy (SCIT) using dog-allergen extract, administered by an allergist. It is NOT a veterinary product. Cytopoint (Zoetis lokivetmab) and Apoquel (Zoetis oclacitinib) are products injected into or given orally to the DOG to treat canine atopic dermatitis — they do not address your IgE sensitization to dog dander. For dogs with skin allergies, see a veterinarian. For YOU being allergic to a dog, this is the right page. This page covers immunotherapy for humans sensitized to dog allergens.
However, before starting dog SCIT, two facts matter enormously. First, the honest evidence reality: Smith DM and Coop CA (Ann Allergy Asthma Immunol 2016;116:188–193) reviewed 17 trials of dog allergen SCIT and concluded 'poor and conflicting results of clinical efficacy, attributed to poor-quality extracts and the inherent complex allergenic profile of dogs that remains without a clearly dominant allergen.' Dog extract is not FDA-standardized — unlike cat-hair and cat-pelt (the only FDA-standardized mammalian extracts in the US, both at 10,000 BAU/mL per Greer license #308), dog extract is PNU-based or w/v with significant lot-to-lot variability. This structural problem makes therapeutic dosing less predictable.
Second, the Can f 5 exit ramp. Can f 5 is a 28 kDa prostatic kallikrein produced exclusively in the prostate gland of intact male dogs — absent in female dogs and neutered males (Mattsson L et al., JACI 2009). Approximately 16.5% of dog-sensitized adults in the West Sweden Asthma Study were monosensitized to Can f 5 (Özuygur Ermis SS et al., Allergy 2023;53:88–104). Schoos AMM et al. (JACI Pract 2020;8:1592–1597) confirmed in a randomized DBPC challenge that 7 of 7 Can f 5-monosensitized children had no reaction to female-dog extract. These patients can adopt a female or neutered dog and skip immunotherapy entirely — making component testing the most useful clinical step before committing to years of shots.
The hypoallergenic-breed myth: Vredegoor JK et al. (JACI 2012;130[4]:904–9) measured Can f 1 in 196 dogs and found 'hypoallergenic' breeds had HIGHER Can f 1 (geometric mean 2.26 µg/g vs 0.77 µg/g for non-hypoallergenic; P<0.001). Nicholas CE et al. (Am J Rhinol Allergy 2011) found detectable Can f 1 in 94% of 173 homes regardless of breed. Curex offers at-home IgE component testing with allergist review for Can f 1, Can f 5, and Can f 3 — distinguishing whether a patient is broadly dog-allergic, sensitized only to intact-male prostatic kallikrein (Can f 5, 16.5% of dog-sensitized adults per Ozuygur Ermis 2023), or primarily cross-reactive to dog via mammalian serum albumin from another species.
How allergy shots retrain your immune system
Dog allergy shots use the same subcutaneous immunotherapy mechanism as other aeroallergen SCIT — escalating allergen doses shifting the IgE response toward IgG4 blocking antibodies and T-regulatory cell tolerance. The challenge for dog SCIT is the absence of a single dominant allergen. Can f 1, the best single predictor at 42–75% sensitization, is not present in all patients' relevant allergen profile, and unstandardized PNU-based extracts may under-represent it.
Component Testing Before Committing
Testing Can f 1, Can f 5, and Can f 3 separately determines the correct treatment path: SCIT/SLIT for Can f 1-dominant patients; female-dog adoption for Can f 5-monosensitized patients; treat primary allergen for Can f 3-dominant (likely cross-reactive from another mammal).
Build-Up Phase (~26 weeks, weekly)
Weekly escalating injections from a fraction of the therapeutic dose. Mandatory 30-minute post-injection observation at every visit per Cox 2011 PP3.
Maintenance Phase (3–5 years, every 2–4 weeks)
Every-2-to-4-week injections for 3–5 years. Unlike cat extract (FDA-standardized), dog extract lacks a defined therapeutic dose target, making consistency across practices variable.
12-Month Clinical Reassessment
Given the weak evidence base, the allergist should formally reassess clinical response after 12 months at maintenance dose. If no meaningful improvement is documented, continuing the multi-year investment has no strong evidence basis.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
Dog SCIT follows the standard three-phase timeline. The visit burden is the same as any SCIT regimen — approximately 39 in-clinic visits in Year 1 — regardless of the weaker efficacy evidence compared to cat or grass SCIT.
Weekly injections escalating to the maintenance dose. A mandatory 30-minute post-injection observation period is required at every visit per Cox 2011 PP3.
Year 1: ~39 total in-clinic visits (build-up + early maintenance). Years 2–5: ~14–20 visits/year. Total course: approximately 95–119 in-clinic visits.
Post-treatment benefit for dog SCIT is poorly characterized. Any residual benefit is extrapolated from general SCIT literature rather than dog-specific long-term RCTs.
Efficacy by allergen — what the data shows
The honest answer is that dog SCIT evidence is substantially weaker than cat, grass, or dust-mite SCIT. Smith 2016's 'poor and conflicting' rating reflects the real-world clinical experience. Patients should make this decision with full knowledge of the evidence gap.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
For dog-allergic patients, the treatment decision depends on component sensitization profile. Can f 5-monosensitized patients have a non-pharmacological alternative (adopting a female or neutered dog), which is the strongest option for that group. Can f 1-dominant patients choose between SCIT — available either in-office or as an at-home allergy shot kit — SLIT drops, and symptomatic pharmacotherapy, with full knowledge that dog SCIT evidence remains 'poor and conflicting.'
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Dog SCIT (Curex) | |||||
SLIT Drops (needle-free, dog-specific) | |||||
Female/Neutered Dog Adoption (Can f 5-mono only) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
Curex delivers conventional dog SCIT as an at-home allergy shot kit for $129/month all-inclusive — the same dog-extract immunotherapy, with its 'poor and conflicting' evidence limits unchanged, given as one weekly shot at home instead of the roughly 39 Year-1 clinic visits the Cox 2011 Practice Parameter requires. The serum is sterile-compounded to USP <797>, a board-certified allergist oversees the plan and reassesses response at 12 months, your first dose and every dose change are supervised live over Zoom, and a prescribed epinephrine auto-injector is confirmed on hand. Can f 5-monosensitized patients should consider adopting a female or neutered dog first.
See if at-home shots are right for youSide effects — what to watch for
Dog SCIT carries the same safety profile as all SCIT. Local reactions are common and expected; systemic reactions are rare but require mandatory in-clinic post-injection observation.
Insurance coverage — what to expect
Dog SCIT is covered by major commercial insurers and Medicare Part B when standard medical necessity criteria are met. For full insurer details, see /allergy-shots/cost/does-insurance-cover-allergy-shots.
Skip the insurance hassle — Curex is $129/mo flat, no insurance needed.
Start free assessmentFrequently asked questions
Is there really an allergy shot for dog allergies in humans?
Yes — it is subcutaneous immunotherapy (SCIT) using dog-allergen extract administered by a board-certified allergist. The important caveat is that dog SCIT has substantially weaker evidence than cat SCIT. Smith DM and Coop CA (Ann Allergy Asthma Immunol 2016;116:188–193) reviewed 17 trials and found 'poor and conflicting results of clinical efficacy,' attributing this to poor-quality extracts and the complex multi-allergen dog profile without a single dominant allergen above 75% sensitization. Dog extract is not FDA-standardized, unlike cat-hair and cat-pelt (10,000 BAU/mL, Greer license #308). This does not mean the shot is useless — some patients report meaningful benefit — but it means patients should make the decision with realistic expectations.
What is Cytopoint and is it for humans?
No. Cytopoint (Zoetis lokivetmab) is a caninized anti-IL-31 monoclonal antibody injected by a veterinarian into dogs every 4–8 weeks to treat canine atopic dermatitis — the dog's own allergic skin condition. It was USDA-licensed in December 2016 and launched in 2017. Cytopoint is not a human drug and does not treat human IgE sensitization to dog dander. It appears in consumer searches for 'allergy shots for dog allergies' because the marketing overlaps with the human-health search space, creating significant consumer confusion. If you are a human allergic to dogs, Cytopoint is irrelevant to your treatment options.
Should I get a 'hypoallergenic' dog instead of allergy shots?
Hypoallergenic dog breeds do not actually produce significantly less Can f 1. Vredegoor JK et al. (JACI 2012;130[4]:904–9) measured Can f 1 in 196 dogs and found hypoallergenic breeds had HIGHER Can f 1 (geometric mean 2.26 µg/g vs 0.77 µg/g for non-hypoallergenic; P<0.001). Nicholas CE et al. (Am J Rhinol Allergy 2011) found no breed effect on Can f 1 levels in 173 homes; 94% had detectable Can f 1 regardless of breed. The only evidence-based breed-based strategy is the Can f 5 monosensitized patient scenario — if your only dog IgE positive is Can f 5, you can adopt a female or neutered dog of any breed and avoid immunotherapy entirely (Schoos 2020 DBPC).
How do I know if I am Can f 5-monosensitized?
Component-resolved IgE blood testing measures specific IgE to Can f 1, Can f 2, Can f 3, Can f 5, and Can f 6 individually. A result showing IgE to Can f 5 only — with negative or very low results for Can f 1, Can f 2, Can f 3 — indicates Can f 5 monosensitization. Per Özuygur Ermis SS et al. (Allergy 2023;53:88–104), approximately 16.5% of dog-sensitized adults in the West Sweden Asthma Study met this profile. Schoos AMM et al. (JACI Pract 2020;8:1592–1597) showed that all 7 Can f 5-monosensitized children in their DBPC challenge had no reaction to female-dog extract. Your allergist can order this test and interpret results in the context of your clinical history.
How long do allergy shots for dog allergies take?
Dog SCIT follows the standard timeline per the AAAAI/ACAAI Practice Parameter Third Update (Cox 2011): approximately 26 weekly build-up injections followed by every-2-to-4-week maintenance for 3–5 years. Year 1 totals approximately 39 in-clinic visits. Years 2–5 require approximately 14–20 visits/year. A 30-minute post-injection observation period is mandatory at every visit. The total course spans approximately 95–119 in-clinic visits over 3–5 years. Given the weak evidence base, the allergist should reassess clinical response at 12 months of maintenance; if no improvement is evident, the rationale for continuing the full course should be re-evaluated.
Is dog SCIT safe even though evidence is weak?
Yes — the safety profile of dog SCIT is the same as all subcutaneous allergen immunotherapy, regardless of the weak efficacy evidence. Local injection-site reactions occur in approximately 30–80% of patients and are normal. Systemic reactions occur in approximately 0.1–0.2% of injection visits (Epstein TG et al., Ann Allergy Asthma Immunol 2014). Fatal anaphylaxis occurs at approximately 1 per 23.3M injection visits across all SCIT allergens. The mandatory 30-minute observation period after every injection is the key safety control, capturing approximately 85% of systemic reactions. If you experience throat tightness, difficulty breathing, generalized hives, or lightheadedness after an injection, call 911 immediately and use an epinephrine auto-injector if available.
Related Articles
Weekly Allergy Shots: Schedule & Missed Doses | Curex
Weekly allergy shots are the conventional SCIT build-up: 24–28 visits over 3–6 months. Learn the dose ladder, missed-dose rules per Cox 2011, and why 23.9% drop out.
Read moreAllergy Shots for Cat Allergy | Full SCIT Guide | Curex
Allergy shots for cat allergies reduce symptoms 60-72% at the 15 mcg Fel d 1 maintenance dose. Cat SCIT efficacy, dosing, and alternatives.
Read moreCat Allergy Shots for Humans | Curex SCIT Guide
Cat allergy shots for humans traditionally mean ~95–119 clinic visits over 3–5 years (23.9% quit, Tkacz 2021). Curex delivers that SCIT at home, $129/mo.
Read morePollen Allergy Shots: Efficacy & Evidence | Curex Guide
Pollen SCIT has the strongest immunotherapy RCT base: grass 49% symptom reduction (Walker 2001), ragweed NEJM 1996, birch 40% (Bødtger 2002). Full regional map inside.
Read moreCat Allergy Shots for Humans | Curex SCIT Guide
Cat allergy shots use FDA-standardized Fel d 1 extract for ~72% symptom relief. RCT evidence, schedule, plus at-home SCIT from Curex at $129/mo.
Read moreAllergy Shots for Dog Allergies | Curex Human SCIT Guide
Allergy shots for dog allergies treat HUMANS — not dogs. Dog SCIT evidence is 'poor and conflicting' (Smith 2016). 16.5% of dog-sensitized adults can skip shots entirely.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.